Most Read Articles
4 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 4 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 2 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.

Three-month height predicts 2-year overweight, obesity in infants small for gestational age

13 Sep 2018

In infants that are small for gestational age (SGA), stunted height at 3 months appears to predict overweight and obesity at 2 years, a recent study has found.

Researchers enrolled 468 SGA infants (mean gestational age 39.49±0.98 weeks; 248 females), in whom the mean height and weight at 3 months were 60.69±1.88 cm and 6.39±0.65 kg, respectively. As a comparison group, 4,642 appropriate for gestational age infants (mean gestational age 39.28±1.06 weeks; 2,135 females) were also enrolled.

At 2 years, 432 of the 468 SGA infants (92.3 percent) demonstrated at least –2 standard deviation scores in height and were determined to have completed height catch up. At birth, infants in the catch-up and noncatch-up groups were comparable in length (49.28±1.80 vs 48.42±2.68 cm; p=0.058), but mean birth weight was significantly lower in the latter group (2.63±0.23 vs 2.45±0.27 kg; p<0.001).

Weight at 3 months became comparable between the two groups (noncatch-up vs catch-up: 6.17±0.91 vs 6.41±0.62 kg; p=0.073), while infants in the catch-up group grew significantly taller (61.10±1.71 vs 59.31±2.84 cm; p<0.001).

After 2 years, mean body mass index was statistically similar between groups (16.20 vs 16.25 kg/m2; p=0.496), but infants in the catch-up group were significantly heavier (12.56±0.68 vs 11.37±0.96 kg; p<0.001) and taller (87.97±1.36 vs 82.88±1.39 cm; p<0.001) than those in the noncatch-up group.

Multivariate logistic regression indicated that the height at 3 months was an independent predictor for catch-up growth at 2 years (odds ratio, 1.621; 95 percent CI, 1.284–2.045; p<0.001).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
4 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 4 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 2 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.